RT Journal Article
SR Electronic
T1 Noscapine Inhibits Human Prostate Cancer Progression and Metastasis in a Mouse Model
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3701
OP 3704
VO 28
IS 6A
A1 ISRAEL BARKEN
A1 JACK GELLER
A1 MOSHE ROGOSNITZKY
YR 2008
UL http://ar.iiarjournals.org/content/28/6A/3701.abstract
AB Background: Noscapine, a non-toxic alkaloid and common constituent of cough medicine, stabilises tubulin. It inhibits the growth of several human and murine neoplasms, with no significant toxicity. Its effect on prostate cancer has not been evaluated. Materials and Methods: Noscapine was administered orally (300 mg/kg per day) for 56 days to PC3 human prostate cancer-bearing immunodeficient mice (n=10). Immunodeficient control mice (n=10) received only diluent in an identical regimen. Results: Mean total tumour weight was 0.42±0.23 g and 0.97±0.31 g (p<0.001) in the noscapine-treated group and the control group, respectively, without evidence of toxicity. Metastases occurred less frequently in the treatment than the control group (30% vs. 90%; p<0.05). Conclusion: Oral administration of noscapine limited tumour growth and lymphatic metastasis of PC3 human prostate cancer in this mouse model, supporting its therapeutic potential as a nontoxic and easily administered treatment for metastatic cancer. Copyright© 2008 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved